Scholarlink

<p>The increasing demand for gastrointestinal endoscopic procedures, coupled with a global shortage of anesthesiologists, underscores the need for intelligent automation in anesthesia care. Reinforcement learning (RL) offers a promising strategy for autonomous anesthesia control, yet prospective clinical validation remains limited. We developed an RL-based automated anesthesia system for gastrointestinal endoscopy (AAS-GE) for automated ciprofol delivery and conducted a prospective, multicenter, randomized controlled trial across four centers in China between January 8 and August 27, 2025. Adults aged 18–65 years with American Society of Anesthesiologists physical status I–II undergoing gastrointestinal endoscopy were randomized 1:1 to receive either AAS-GE–controlled anesthesia or clinician-managed manual anesthesia. The primary outcome was the incidence of hypoxemia, defined as oxygen saturation below 92%, with secondary outcomes assessing hypoxemia severity, induction time, drug use, recovery, and adverse events. A total of 509 participants were included in algorithm development, and 418 were enrolled for clinical validation. The incidence of hypoxemia was comparable between groups (14.42 vs. 14.29%; odds ratio 1.01, 95% CI 0.59–1.75; <i>P</i> = 0.968), with no significant differences in secondary safety outcomes. AAS-GE achieved a shorter induction time (median 1.55 vs. 1.90 min; <i>P</i> &lt; 0.001) without increasing total drug dose or recovery time. However, intraoperative body movement was more frequent in the AAS-GE group, consistent with lighter anesthesia depth. These results demonstrate the non-inferior safety and efficacy of AAS-GE compared with clinician management, supporting its potential to improve efficiency and standardize sedation care. Clinical registration: ClinicalTrials.gov on Feb. 26, 2025 (NCT06857344).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reinforcement learning based automated anesthesia system for gastrointestinal endoscopy with a multicenter randomized trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Hai-Long Bing,
  • Yan Wang,
  • Shi-Ying Li,
  • Yuan-Wen Li,
  • Qi-Min Wang,
  • Liu-Mei Li,
  • Sheng-Qun Liu,
  • Zhen-Hua Hu,
  • Tian-Wei Wang,
  • Qing-Wang Lu,
  • Ran Ran,
  • Yi Wu,
  • Shu-Sheng Xu,
  • Hui-Jie Li,
  • Jian Huo,
  • Chen Liu,
  • An-Min Hu,
  • Zheng-Yuan Xia,
  • Qin-Jun Chu

摘要

The increasing demand for gastrointestinal endoscopic procedures, coupled with a global shortage of anesthesiologists, underscores the need for intelligent automation in anesthesia care. Reinforcement learning (RL) offers a promising strategy for autonomous anesthesia control, yet prospective clinical validation remains limited. We developed an RL-based automated anesthesia system for gastrointestinal endoscopy (AAS-GE) for automated ciprofol delivery and conducted a prospective, multicenter, randomized controlled trial across four centers in China between January 8 and August 27, 2025. Adults aged 18–65 years with American Society of Anesthesiologists physical status I–II undergoing gastrointestinal endoscopy were randomized 1:1 to receive either AAS-GE–controlled anesthesia or clinician-managed manual anesthesia. The primary outcome was the incidence of hypoxemia, defined as oxygen saturation below 92%, with secondary outcomes assessing hypoxemia severity, induction time, drug use, recovery, and adverse events. A total of 509 participants were included in algorithm development, and 418 were enrolled for clinical validation. The incidence of hypoxemia was comparable between groups (14.42 vs. 14.29%; odds ratio 1.01, 95% CI 0.59–1.75; P = 0.968), with no significant differences in secondary safety outcomes. AAS-GE achieved a shorter induction time (median 1.55 vs. 1.90 min; P < 0.001) without increasing total drug dose or recovery time. However, intraoperative body movement was more frequent in the AAS-GE group, consistent with lighter anesthesia depth. These results demonstrate the non-inferior safety and efficacy of AAS-GE compared with clinician management, supporting its potential to improve efficiency and standardize sedation care. Clinical registration: ClinicalTrials.gov on Feb. 26, 2025 (NCT06857344).